#1 Clinical Trials Search in Europe

Allo-647

ALLO-647 is an experimental antibody being studied in clinical trials for patients with relapsed or refractory large B-cell lymphoma (LBCL). This article will provide an overview of the ongoing research, including its potential benefits, how it works, and what patients can expect from participating in these trials. The studies aim to evaluate the safety and effectiveness of ALLO-647 when used in combination with other treatments for this challenging form of lymphoma.

Table of Contents

What is ALLO-647?

ALLO-647 is an experimental medication being developed to treat a specific type of blood cancer. It is a recombinant humanized monoclonal antibody, which means it’s a laboratory-made protein designed to mimic antibodies naturally produced by the human immune system[1]. This drug is being studied as part of a new approach to cancer treatment that involves using the body’s own immune system to fight cancer cells.

How does ALLO-647 work?

ALLO-647 works as part of a treatment process called lymphodepletion. Lymphodepletion is a procedure that temporarily reduces the number of certain immune cells in the body. This is done to prepare the body for a special type of cancer treatment called CAR T-cell therapy.

In the studies, ALLO-647 is used alongside two chemotherapy drugs, fludarabine and cyclophosphamide. This combination helps to create space in the patient’s body for the CAR T-cells (in this case, a treatment called ALLO-501A) to work more effectively[1][2].

What condition does ALLO-647 treat?

ALLO-647 is being studied to treat Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL). This is a type of blood cancer that affects white blood cells called B lymphocytes. “Relapsed” means the cancer has returned after treatment, while “refractory” means the cancer has not responded to treatment[1][2].

Clinical Trials for ALLO-647

ALLO-647 is currently being studied in clinical trials. These are research studies that help doctors understand how well a new treatment works and if it’s safe. Two main trials are currently ongoing:

  1. The ALPHA2 trial: This is a Phase 1/2 study looking at the safety and effectiveness of ALLO-647 when used with ALLO-501A (the CAR T-cell therapy) in adults with R/R LBCL[1].

  2. The EXPAND trial: This is a Phase 2 study comparing lymphodepletion with fludarabine, cyclophosphamide, and ALLO-647 versus fludarabine and cyclophosphamide alone in patients receiving ALLO-501A[2].

How is ALLO-647 administered?

ALLO-647 is given as an intravenous injection, which means it’s delivered directly into the bloodstream through a vein. In the clinical trials, it’s administered as part of the lymphodepletion process, which occurs over about a week before the CAR T-cell therapy (ALLO-501A) is given[1][2].

Who is eligible for ALLO-647 treatment?

The clinical trials have specific criteria for who can participate. Generally, eligible patients are adults with R/R LBCL who have tried at least two other types of treatment without success. Other criteria include:

  • Having at least one measurable tumor
  • Being in relatively good overall health (able to carry out light daily activities)
  • Having adequate function of bone marrow, kidneys, and liver
  • Not having active cancer in the central nervous system (brain and spinal cord)[1][2]

Safety and Side Effects

As ALLO-647 is still in clinical trials, all of its potential side effects are not yet known. The trials are closely monitoring for any adverse events (unwanted effects). Some areas of particular interest include:

  • Infusion-related reactions
  • Cytopenias (low blood cell counts)
  • Infections
  • Cytokine release syndrome (a condition that can cause fever, nausea, headache, rash, rapid heartbeat, low blood pressure, and trouble breathing)
  • Graft-versus-host disease (where donor cells attack the recipient’s body)[1][2]

Future Prospects

If the clinical trials show that ALLO-647 is safe and effective, it could become an important part of treatment for people with R/R LBCL who haven’t responded to other therapies. The researchers will continue to monitor patients for up to 15 years to understand the long-term effects of this treatment[1][2].

It’s important to remember that ALLO-647 is still experimental and not yet approved for general use. If you have R/R LBCL and are interested in this treatment, talk to your doctor about whether participating in a clinical trial might be right for you.

Aspect Details
Drug Name ALLO-647
Type Experimental antibody
Condition Studied Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Administration Intravenous use
Used In Combination With Fludarabine, Cyclophosphamide, and ALLO-501A (CAR T cell therapy)
Primary Objectives Assess safety and efficacy, measure progression-free survival
Secondary Objectives Evaluate overall response rate, duration of response, cellular kinetics, immunogenicity
Key Eligibility Criteria Adults with R/R LBCL, at least 2 prior lines of chemotherapy, adequate organ function
Safety Monitoring Adverse events, infusion reactions, cytopenias, infections, CRS, neurotoxicity
Follow-up Period Up to 5 years, with option for additional 10 years in separate study

FAQ

  • What is ALLO-647? ALLO-647 is an experimental antibody being studied in clinical trials for patients with relapsed or refractory large B-cell lymphoma (LBCL). It is used as part of a lymphodepletion regimen before administering ALLO-501A, which is a type of allogeneic CAR T cell therapy.
  • How is ALLO-647 administered? ALLO-647 is administered intravenously (through a vein) as part of a lymphodepletion regimen. It is typically given along with other chemotherapy drugs like fludarabine and cyclophosphamide before the patient receives ALLO-501A treatment.
  • What are the main objectives of the clinical trials involving ALLO-647? The main objectives of these trials are to assess the safety and efficacy of ALLO-647 when used in combination with other treatments for LBCL. Researchers are particularly interested in how it affects progression-free survival, overall response rates, and the depth and duration of lymphodepletion.
  • Who is eligible to participate in these clinical trials? Eligible participants typically include adults with relapsed or refractory large B-cell lymphoma who have received at least two prior lines of chemotherapy. They must also meet specific criteria regarding their overall health status, including adequate organ function and absence of certain medical conditions.
  • What are the potential benefits and risks of participating in these trials? Potential benefits include access to a new treatment that may be more effective than standard options for relapsed/refractory LBCL. However, as with any clinical trial, there are risks of side effects and the possibility that the treatment may not be effective. Common side effects being monitored include infusion-related reactions, cytopenias (low blood cell counts), and infections.

Ongoing Clinical Trials on Allo-647

  • Study on the Safety and Effectiveness of ALLO-501A and ALLO-647 for Adults with Relapsed or Refractory Large B-Cell Lymphoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Spain

  • Study on ALLO-647 and ALLO-501A for Adults with Relapsed or Refractory Large B-Cell Lymphoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Germany

Glossary

  • Large B-Cell Lymphoma (LBCL): A type of aggressive cancer that affects B lymphocytes, a kind of white blood cell. It is the most common type of non-Hodgkin lymphoma.
  • Relapsed/Refractory (R/R): Refers to cancer that has returned after treatment (relapsed) or has not responded to initial treatment (refractory).
  • ALLO-647: An experimental antibody being studied for use in lymphodepletion before CAR T cell therapy in patients with large B-cell lymphoma.
  • ALLO-501A: An allogeneic CAR T cell therapy designed to recognize and fight large B-cell lymphoma cells.
  • Lymphodepletion: A process of reducing the number of lymphocytes in the body, typically done before certain cancer treatments to improve their effectiveness.
  • CAR T cell therapy: A type of treatment in which a patient's T cells (a type of immune cell) are changed in the laboratory to attack cancer cells.
  • Allogeneic: Referring to cells or tissues that are taken from a different individual of the same species.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Duration of Response (DOR): The length of time that a tumor continues to respond to treatment without growing or spreading.
  • Cytokine Release Syndrome (CRS): A condition that can occur after some cancer treatments, causing symptoms such as fever, nausea, headache, rash, rapid heartbeat, low blood pressure, and trouble breathing.
  • Graft-Versus-Host Disease (GVHD): A potential complication of allogeneic treatments where the donor cells attack the recipient's tissues.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-allo-501a-and-allo-647-for-adults-with-relapsed-or-refractory-large-b-cell-lymphoma/
  2. http://clinicaltrials.eu/trial/study-on-allo-647-and-allo-501a-for-adults-with-relapsed-or-refractory-large-b-cell-lymphoma/